Oculis (NASDAQ:OCS) Reaches New 12-Month Low - Should You Sell?

Key Points

• Oculis shares hit a new 52-week low, trading as low as $9.65 and last changing hands near $9.35, well below the 50-day and 200-day moving averages of $11.86 and $18.51.
• Despite the decline, analyst sentiment remains broadly positive: nine analysts rate Oculis a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $39.44.
• Oculis remains a high-risk, clinical-stage biotech, reporting a quarterly loss of $0.20 per share, only $0.38 million in revenue, and negative return on equity; institutional investors own 22.3% of the stock.

Oculis Holding AG (NASDAQ:OCS - Get Free Report)'s share price hit a new 52-week low on Thursday . The stock traded as low as $9.65 and last traded at $9.3460, with a volume of 6271 shares. The stock had previously closed at $9.99.

Analyst Ratings Changes

OCS has been the topic of a number of analyst reports. Needham & Company LLC decreased their target price on shares of Oculis from $46.00 to $38.00 and set a "buy" rating on the stock in a research report on Monday, June 1st. Stifel Nicolaus dropped their price target on shares of Oculis from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, June 1st. JPMorgan Chase & Co. cut their price target on Oculis from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Friday, August 14th. Guggenheim reduced their price target on Oculis from $75.00 to $45.00 and set a "buy" rating on the stock in a research report on Monday, June 1st. Finally, HC Wainwright raised their price objective on Oculis from $26.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday, September 18th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $39.44.

Oculis Price Performance

The business's 50 day moving average is $11.86 and its 200-day moving average is $18.51. The firm has a market capitalization of $546.46 million, a P/E ratio of -5.45 and a beta of 0.52. The company has a quick ratio of 8.35, a current ratio of 8.35 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $0.38 million for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. As a group, sell-side analysts predict that Oculis Holding AG will post -2.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC lifted its holdings in shares of Oculis by 326.4% in the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company's stock worth $854,000 after acquiring an additional 47,158 shares during the last quarter. Braidwell LP bought a new stake in shares of Oculis during the 2nd quarter valued at approximately $11,570,000. Bank of America Corp DE increased its position in Oculis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company's stock worth $1,855,000 after purchasing an additional 5,813 shares in the last quarter. Himension Capital Singapore PTE. LTD. bought a new position in Oculis in the 1st quarter valued at approximately $503,000. Finally, Koshinski Asset Management Inc. bought a new position in Oculis in the 1st quarter valued at approximately $238,000. Institutional investors and hedge funds own 22.30% of the company's stock.

About Oculis

Oculis is a clinical-stage biopharmaceutical company focused on developing ophthalmic therapies for eye diseases and vision loss. The company uses proprietary drug-delivery technologies designed to improve the delivery of treatments to specific tissues in the eye, with the goal of offering effective and convenient alternatives to injections or other invasive procedures.

Oculis' pipeline includes OCS-01, a topical eye-drop formulation of dexamethasone being developed for diabetic macular edema and inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.